Ad-Hoc News

Zurück
16.12.24
Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 Fiscal Year
21.11.24
Xlife Sciences AG Announces the listing of FUSE-AI GmbH on the London Stock Exchange in the First Half of 2025
30.9.24
Xlife Sciences AG enables international co-investors to enter the stock and is planning a dual listing on the London Stock Exchange Group (LSEG)
19.9.24
Xlife Sciences AG: Successful First Half of 2024 with Strategic Progress and Solid Financial Figures
3.9.24
Xlife Sciences AG Completes Strategic Review Process by Q3 2024
30.4.24
Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report
23.4.24
Xlife Sciences AG Publishes 2023 Annual Report
29.12.23
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline
18.12.23
Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Registration
18.10.23
Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million
21.9.23
Xlife Sciences with significant progress in H1 2023
17.8.23
Collaboration of Xlife Sciences and the Department of Health – Abu Dhabi to drive global innovations in the life sciences sector
26.5.23
Xlife Sciences publishes agenda for Annual General Meeting 2023
27.4.23
Xlife Sciences: Valuation Report 2022 confirms and emphasizes long-term portfolio potential
20.4.23
Xlife Sciences publishes 2022 results and 2023 outlook
16.2.23
saniva diagnostics receives approval from the US FDA for its medical product NeuroMex
21.11.22
Xlife Sciences initiates a review of strategic options
28.9.22
Xlife Sciences with pleasing progress in the first half of 2022
9.5.22
Xlife Sciences: First Valuation Report confirms substancial potential of the project portfolio and assumes CHF 574 million in the most conservative scenario
29.4.22
Annual Report 2021 (only available in german)
25.4.22
License partner of Xlife Sciences announces successful completion of phase 1 of in-vivo trial for ATROSIMAB – out-licensing of the compound intended
21.4.22
Xlife Sciences: Date of publication Annual Report 2022
8.3.22
Laxxon Medical, a project company of Xlife Sciences, wins Evonik as investor and partner
11.2.22
Xlife Sciences' shares begin trading on SIX Swiss Exchange
8.2.22
Xlife Sciences publishes prospectus for listing on SIX Swiss Exchange
1.2.22
Listing and first trading day on the “Sparks” segment of SIX Swiss Exchange expected for February 11, 2022
10.1.22
Xlife Sciences (XLS DE) plans listing on the “Sparks” segment of SIX Swiss Exchange
18.11.21
Xlife Sciences (XLS DE) explores listing on SIX Swiss Exchange
26.10.21
Partnership with Vision 2030
10.6.21
Xlife Sciences AG (XLS DE): Breakthrough in Drug Development
31.3.21
Xlife Sciences AG (XLS): 2020 financial results
17.2.21
Xlife Sciences AG (XLS): Antiviral drug candidate
8.1.21
Xlife Sciences AG: Transaction with Baliopharm AG
23.12.20
Xlife Sciences AG: Exit of a project company
5.8.20
Xlife Sciences AG: Xlife Sciences takes stake in palleos healthcare
14.2.20
Xlife Sciences AG: Announcement of «Private Placement» capital increase (German only)
22.11.19
Xlife Sciences AG: Xlife Sciences AG issues convertible bond (German only)
11.3.20
Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)